Pharmacorp Files Q3 2024 Financial Statements And MD&A
Pharmacorp Files Q3 2024 Financial Statements And MD&A . (MENAFN - GlobeNewsWire - Nasdaq) SASKATOON, Saskatchewan, Nov. 26, 2024 (GLOBE NEWSWIRE) --  PHARMACORP RX INC.  (–  PharmaCorp – or the–  Corporation –) (TSXV: PCRX) is pleased to announce the ...
América - MenaFN
(MENAFN- GlobeNewsWire - Nasdaq) SASKATOON, Saskatchewan, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PHARMACORP RX (“ PharmaCorp ” or the“ Corporation ”) (TSXV: PCRX) is pleased to announce the filing on SEDAR+ of its unaudited statements together with associated MD&A for the three and nine months ended September 30, 2024. To review the Corporation's Q3 2024 unaudited financial statements and associated MD&A please visit SEDAR+ at .

About PharmaCorp Rx Inc.

PharmaCorp currently operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada branded pharmacies as they come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The Corporation will also acquire independently owned non-PharmaChoice Canada bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a ‎PharmaChoice Canada banner. PharmaCorp shares trade on the TSX Venture Exchange under the symbol: PCRX.

For further information, contact:

Mr. Alan Simpson

Suite #203, 303 Wellman Lane, Saskatoon, SK S7T 0J1 ‎

Tel: (306) 536-3771

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108930080/Pharmacorp-Files-Q3-2024-Financial-Statements-And-MDA
2024-11-26
rss
(MENAFN - GlobeNewsWire - Nasdaq) SASKATOON, Saskatchewan, Nov. 26, 2024 (GLOBE NEWSWIRE) --  PHARMACORP RX INC.  (–  PharmaCorp – or the–  Corporation –) (TSXV: PCRX) is pleased to announce the ...
Pharmacorp Files Q3 2024 Financial Statements And MD&A